Lupin Soars As Plant-Related Concerns Fade
This article was originally published in Scrip
Executive Summary
Diminishing plant-related concerns lifted shares of Lupin on Indian bourses after the US FDA approved the firm's fenofibrate tablets 54 mg and 160 mg, generic versions of Teva's fenofibrate of the same strengths, the current reference listed drug.